Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Lyle Craker, Ph.D., MAPS Founder Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Meadow

JULY 13, 2018

we want everyone who did not have the opportunity to attend Meadowlands to have access to this content. Back in 2007, it said we don’t want anymore cannabis businesses and despite a general prohibition, we still had more cannabis businesses than any other location. So in L.A., we know you have a cap for 400 retail locations.

Wellness and Beauty 40

Wellness and Beauty Policy Consumption Cannabis 40

Cannabis Law Report

MARCH 25, 2019

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 3, 2010 , 124 Stat. 2003, 2004, 2007, 2008, Nov. 109–248, title II , § ? 611 ; Pub. 110–425 , § ?

Banking 45

Banking Law Marijuana State Laws 45

The Joint Blog

JUNE 2, 2020

In 2007, he acknowledged that ending raids on medical marijuana users was necessary, but that he believed that “there’s got to be a better answer than marijuana” for addressing health issues and symptoms. He voiced the long-debunked theory in 2010 that marijuana serves as a “gateway drug” to dangerous substances. Tulsi Gabbard Rep.

Decriminalization 29

Decriminalization Recreational Advocacy Policy 29